Spravato vs. Seroquel: Ketamine's Superiority in Treatment-Resistant Depression and Expanding Formulations

The podcast provides an update on ketamine's role in treating depression, particularly treatment-resistant depression (TRD), two years after Dr. Tracey Marks last discussed it. Ketamine, originally an anesthetic, is highlighted for its rapid antidepressant effects, working through neuroplasticity and increasing brain-derived neurotrophic factor (BDNF), a mechanism distinct from traditional antidepressants that target serotonin, norepinephrine, and dopamine. A key benefit emphasized is its ability to resolve suicidal thinking within hours, making it a crucial intervention for severe cases.\n\nThe episode details new developments, including the 2019 FDA approval of Spravato (esketamine nasal spray) for TRD, which was initially used off-label intravenously. A significant finding from a recent 2023 study is presented: Spravato was found to be far superior to Quetiapine (Seroquel), an antipsychotic used for TRD, schizophrenia, and bipolar disorder, in a head-to-head comparison. This drug-to-drug comparison is underscored as a higher level of research, providing more meaningful insights into a drug's true efficacy compared to established treatments, rather than just placebo.\n\nPractically, these findings mean that individuals struggling with chronic depression now have a more effective and potentially safer option. While Spravato requires supervised administration and can cause dissociation and increased blood pressure, it avoids the weight gain and metabolic changes associated with Quetiapine. The increasing availability of Spravato, with better insurance coverage after four years on the market, makes it more accessible. Furthermore, another recent study supports the safety and effectiveness of ketamine injections, offering an additional, potentially cheaper, non-FDA-approved option from compounding pharmacies, though intravenous ketamine remains the most potent and rapid-acting formulation.\n\nThe broader implications suggest a growing body of research supporting diverse ketamine formulations for TRD, expanding treatment options beyond traditional methods. The discussion points to a future where neuroplasticity-targeting drugs play a more central role in mental health. Dr. Marks also briefly touches on psychedelics as "the next big thing" and ongoing research into suicide, positioning ketamine as a significant advancement in the evolving landscape of psychiatric care, offering hope for those who have not responded to conventional treatments.

"Ketamine is a medication primarily used for starting and maintaining anesthesia."

"It's gained a lot of attention for its rapid acting antidepressant effects, especially for treating depression that has not responded to at least two antidepressants."

"Ketamine works at the level of neuroplasticity or rewiring the brain."

"It can also immediately resolve suicidal thinking within hours."

"In 2019, ketamine nasal spray called bravado, was officially FDA approved for treatment resistant depression."

"A recent study from 2023 compared PROVATO to QUETIAPINE for treatment resistant depression and Provato was found to be far superior to QUETIAPINE for treating severe depression."

"Drug two drug comparisons are next level research and give us perspective on just how good or not so good a medicine is compared to something that's tried and true."

"It means that people who are struggling with chronic depression may have a more effective and safer option."

"The grand prize still goes to intravenous ketamine in terms of how fast it works and how powerfully it resolves symptoms, including suicidality."

"Research support for using ketamine for treatment resistant depression is building and expanding to different formulations that are also effective."